Compare AER & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | GMAB |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | Ireland | Denmark |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 19.1B |
| IPO Year | 2006 | N/A |
| Metric | AER | GMAB |
|---|---|---|
| Price | $135.14 | $26.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $150.29 | $40.93 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.80 |
| Revenue Next Year | $1.53 | $14.86 |
| P/E Ratio | $7.27 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $85.57 | $17.24 |
| 52 Week High | $154.94 | $35.43 |
| Indicator | AER | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 33.14 |
| Support Level | $129.85 | $20.83 |
| Resistance Level | $138.34 | $33.75 |
| Average True Range (ATR) | 4.30 | 0.61 |
| MACD | -1.63 | -0.10 |
| Stochastic Oscillator | 14.96 | 11.59 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.